6
Participants
Start Date
January 31, 2017
Primary Completion Date
April 30, 2018
Study Completion Date
April 30, 2019
Avelumab
Avelumab 10mg/kg IV on days 1 and 15 of each 28-day cycle. Treatment will be given until disease progression, unacceptable toxicity, investigator decision or patient withdrawal.
UC San Diego Moores Cancer Center, La Jolla
Dana-Farber Cancer Institute, Boston
Collaborators (1)
Pfizer
INDUSTRY
Assuntina Sacco, M.D.
OTHER